Huntington's Disease clinical trials at UCSF
4 in progress, 2 open to new patients
-
Cooperative Huntington's Observational Research Trial
open to all eligible people
The purpose of this study is to collect prospective data from individuals who are part of a Huntington Disease (HD) family, in order to relate phenotypes between individuals and families with each other and genetic factors in order to learn more about HD, develop potential treatments for HD, and to plan for future research studies of experimental drugs aimed at slowing or postponing the onset and progression of HD.
San Francisco, California and other locations
-
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
open to eligible people ages 18 years and up
Enroll-HD is a longitudinal, observational, multinational study that will integrate two existing Huntington's Disease (HD) registries, REGISTRY in Europe and COHORT in North America and Australia, while also expanding to include sites in Latin America and Asia. With no end date and annual assessments, the goal of Enroll-HD is to build a large and rich database of longitudinal clinical information and biospecimens. This database will serve as a basis for future studies aimed at developing tools and biomarkers for progression and prognosis, identifying clinically relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies.
San Francisco, California and other locations
-
A Clinical Study in Subjects With Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod
Sorry, in progress, not accepting new patients
The primary objective of this study is to assess the efficacy of laquinimod 0.5, 1.0, and 1.5 mg qd in patients with HD after 12 months of treatment using the UHDRS-TMS.
San Francisco, California and other locations
-
Neurobiological Predictors of Huntington's Disease (PREDICT-HD)
Sorry, in progress, not accepting new patients
The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.